▲ +560.71% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Liquidia in the last 3 months. The average price target is $18.50, with a high forecast of $40.00 and a low forecast of $4.00. The average price target represents a 560.71% upside from the last price of $2.80.
The current consensus among 4 contributing investment analysts is to buy stock in Liquidia. This rating has held steady since March 2020, when it changed from a Hold consensus rating.
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.